UTHR United Therapeutics (UTHR) Q4 FY25 earnings call
United Therapeutics delivered strong Q4 FY25 results, driven by double-digit growth in key products like Tyvaso. The company is poised for a transformative period with three major product launches expected by 2027: Tresmi (a coughless soft mist inhaler), a once-daily super prostacyclin, and an improved IPF treatment. Management reaffirmed its commitment to double-digit revenue growth and a $4 billion run rate by late 2026, independent of these new launches, while also advancing its xenotransplantation and AI-enabled drug discovery programs.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.